Abstract
The αvβ3 receptor, which are members of the group of the cellular adhesion molecules (CAM), are heterodimeric transmembrane glycoprotein receptors involved in processes such as cell-cell and cell-matrix adhesion, cell migration and signaling. Integrin αvβ3 receptor is expressed on almost all cells originating from the mesenchyme and seem to mediate several biological processes, including adhesion of osteoblasts to the bone matrix, migration of vascular smooth muscle cells, and angiogenesis. Many efforts were done in the last 10 years to individuate inhibitors for αvβ3 receptors, due to their involvement in important pathophysiological functions. In fact, selective αvβ3 antagonists offer new therapeutic opportunities for the treatment of several human pathologies like osteoporosis, restenosis and diseases involving neovascularization such as rheumatoid arthritis, tumor induced angiogenesis and metastasis. Purpose of this account is to summarize the recent developments in the field of non-peptidic αvβ3 antagonists.
Keywords: integrins, cellular adhesion molecules, crystal structure, vitronectin receptor, osteoblasts, carcinoma
Current Medicinal Chemistry
Title: Non Peptidic αvβ3 Antagonists: Recent Developments
Volume: 12 Issue: 1
Author(s): Barbara Cacciari and Giampiero Spalluto
Affiliation:
Keywords: integrins, cellular adhesion molecules, crystal structure, vitronectin receptor, osteoblasts, carcinoma
Abstract: The αvβ3 receptor, which are members of the group of the cellular adhesion molecules (CAM), are heterodimeric transmembrane glycoprotein receptors involved in processes such as cell-cell and cell-matrix adhesion, cell migration and signaling. Integrin αvβ3 receptor is expressed on almost all cells originating from the mesenchyme and seem to mediate several biological processes, including adhesion of osteoblasts to the bone matrix, migration of vascular smooth muscle cells, and angiogenesis. Many efforts were done in the last 10 years to individuate inhibitors for αvβ3 receptors, due to their involvement in important pathophysiological functions. In fact, selective αvβ3 antagonists offer new therapeutic opportunities for the treatment of several human pathologies like osteoporosis, restenosis and diseases involving neovascularization such as rheumatoid arthritis, tumor induced angiogenesis and metastasis. Purpose of this account is to summarize the recent developments in the field of non-peptidic αvβ3 antagonists.
Export Options
About this article
Cite this article as:
Cacciari Barbara and Spalluto Giampiero, Non Peptidic αvβ3 Antagonists: Recent Developments, Current Medicinal Chemistry 2005; 12 (1) . https://dx.doi.org/10.2174/0929867053363522
DOI https://dx.doi.org/10.2174/0929867053363522 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of IL-17 on Cells of the Monocyte Lineage in Health and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Chemokine Inhibitors as Anti-Inflammatory Drugs (Executive Editor: David J. Grainger)]
Mini-Reviews in Medicinal Chemistry Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation
Current Drug Targets Novel, Acidic CCR2 Receptor Antagonists: Lead Optimization
Letters in Drug Design & Discovery Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies
Current Drug Targets Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review
Current Medicinal Chemistry CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism Ankylosing Spondylitis and Pregnancy: A Literature Review
Current Rheumatology Reviews Adenosine and Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
Current Pharmaceutical Design Discovery of Lansoprazole and its Unique Pharmacological Properties Independent from Anti-secretory Activity
Current Pharmaceutical Design Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences
Central Nervous System Agents in Medicinal Chemistry Differential TNF-Signaling in Chronic Inflammatory Disorders
Current Molecular Medicine The Phenotypic and Metabolic Characteristics of Neutrophils in Normal Pregnancy and Preeclampsia
Current Immunology Reviews (Discontinued) Thymoquinone Shows the Diverse Therapeutic Actions by Modulating Multiple Cell Signaling Pathways: Single Drug for Multiple Targets
Current Pharmaceutical Biotechnology Non-enzymatic Glycation of Almond Cystatin Leads to Conformational Changes and Altered Activity
Protein & Peptide Letters